Phase III Setback For Merck's Antithrombotic Damages One Of The Key Assets Of The Schering Merger
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck does not yet know why DSMB decided no longer to study vorapaxar in stroke and ACS patients, but market analysts suspect a finding of excess bleeding.
You may also be interested in...
Merck’s CV Pipeline: A Shrinking But Strident Commitment
Merck insists it is committed to its cardiovascular franchise, but the company has had to halt the development of several CV assets and has been plagued by poor trial results for others.
Bleeding Rates In TRA-2P Further Dim Outlook For Merck’s Vorapaxar
Outcomes study of about 25,000 patients shows novel antiplatelet drug reduces events but also increases major bleeding, including intracranial hemorrhage.
Bleeding Rates In TRA-2P Further Dim Outlook For Merck’s Vorapaxar
Outcomes study of about 25,000 patients shows novel antiplatelet drug reduces events but also increases major bleeding, including intracranial hemorrhage.